|
|
| Custom Cloud Molded Shoe gets CMS approval | | July 23, 2008 (USA) |  |
CrocsRx, the medical division of Crocs Inc, announced the Center for Medicare and Medicaid Services (CMS) has accepted the Custom Cloud model into the diabetic shoe program. Acceptance by the CMS validates the superior benefits of Croslite material, Crocs proprietary closed-cell resin, as the Custom Cloud is the first molded shoe to receive an approved code verification from the organization.
Effective immediately, medical professionals can fit the more than 23 million Americans suffering from diabetes in the CrocsRx Custom Cloud. The approved shoe comes with three pairs of heat moldable orthotic insoles and is fitted by a professional practitioner, to offer long-term relief for foot ailments related to the disease.
Recognized by the American Podiatric Medical Association with its distinguished Seal of Acceptance, the Custom Cloud offers diabetic patients several advantages over traditional specialty footwear.
Among the most notable benefit is the customized fit that stems from the Croslite Ag+ material. Croslite Ag+ material expands upon the comfort attributes inherent to Croslite material while adding anti-bacterial, anti-fungal and odor resistant nano-Silver ceramic crystals.
Moreover, patients find the Custom Cloud to be easier to slip on, easier to keep clean and that the shoe weighs less than other specialty medical footwear styles accepted by CMS. The Custom Cloud is available in three color combinations including Navy, Black and Chocolate in men’s size 4-13.5 and women’s size 6-13.5, with four width offerings.
“We are thrilled with the Center for Medicare and Medicaid’s decision to include CrocsRx footwear in the Medicare program,” stated Eddie Scott, Director of CrocsRx. “CMS acceptance is an enormous accomplishment as this governing body completed an extensive review of clinical and historical performance data and found Croslite material to be a suitable alternative to existing specialty leather footwear.” | | | | Crocs Inc |  |
| |
|
|
|
|